News & Events

Clinigen Group Named Business of the Year at the European Business Awards

Clinigen Group Named Business of the Year at the European Business Awards

Burton-on-Trent, UK – 28 May 2015 – Clinigen Group plc (‘Clinigen’ or the ‘Group’, AIM: CLIN), the specialty global pharmaceutical company, has been named the winner of the Business of the Year Award with Turnover of €26-150m at Tuesday’s 2014/15 European Business Awards Gala Ceremony in London.

Peter George, Chief Executive Officer, Clinigen Group said: “I am immensely proud that Clinigen has been recognized as Business of the Year across all of Europe. This is a huge achievement and testament to how far the Group has come over the last year as we continue in our mission to deliver the right drug to the right patient at the right time.”

Clinigen was one of only 10 companies in Europe to be shortlisted for the Business of the Year with Turnover of €26-150m category and one of 11 overall category winners out of over 20,000 applicants from 33 countries.

The Group has been previously been named as one of over 700 European ‘National Champions’ by a judging panel consisting of European business and political leaders, academics and entrepreneurs. It was also recognized by the European Business Awards as one of only 110 Ruban d’Honneur finalists in February.

Adrian Tripp, CEO of the European Business Awards said: “Our winners are shaping the face of European business and helping keep Europe’s position as a leading player on the global business stage. Huge congratulations to Clinigen Group for their success.”

The Business of the Year Award recognizes companies that successfully demonstrate financial returns, strong growth, innovation and market leadership in their sectors. In 2011 Clinigen was named the fastest growing company in the UK by the Sunday Times Virgin Fast Track 100. The Group joined the London Stock Exchange’s AIM in September 2012, the first UK healthcare company to list in London in five years, and won Best Newcomer at the AIM Awards in 2013. In April 2015 Clinigen acquired Idis, creating the market leader in the ethical unlicensed supply of medicines.

Clinigen has seen six-fold revenue growth over the past four years and has increased profit margins from 8% to 20%. The Group is committed to best practice and operating as an award-winning company.

About Clinigen Group
The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. The Group is dedicated to delivering ‘the right drug, to the right patient at the right time’. In April 2015, Clinigen acquired Idis, the market leader in the global supply of unlicensed medicines. The Group now operates as four synergistic businesses; Clinigen Specialty Pharmaceuticals, Clinigen Clinical Trials Supply, Idis Managed Access Programs (this now includes the previously branded Clinigen Global Access Programs business) and Idis General Access.

For more information, please visit

About the European Business Awards:
The European Business Awards’ primary purpose is to support the development of a stronger and more successful business community throughout Europe. For all of the citizens of Europe, our prosperity, social and healthcare systems are reliant on businesses creating an even stronger, more innovative, successful, international and ethical business community - one that forms the beating heart of an increasingly globalised economy.

The European Business Awards programme serves the European business community in three ways:

  • It celebrates and endorses individuals’ and organisations’ success
  • It provides and promotes examples of excellence for the business community to aspire to
  • It engages with the European business community to create debate on key issues

The European Business Awards is now in its 9th year. It attracted over 24,000 businesses to the competition last year and in the public vote generated over 170,000 votes from across Europe.

Issued for and on behalf of Clinigen Group by Instinctif Partners.

For more information please contact:

back to news


Melanie Toyne-SewellManaging Partner